SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
SciSparc (Nasdaq: SPRC) announced that its venture, MitoCareX Bio , has validated the potential significant involvement of its target SLC25 carrier protein in Non-Small Cell Lung Cancer (NSCLC) cells. The discovery was demonstrated using genetic manipulations and 3D spheroid systems, mimicking human solid tumors. NSCLC, accounting for 80%-85% of all lung cancer cases globally, is projected to reach a market value of $59.77 billion by 2030.
MitoCareX previously screened millions of small molecules using its proprietary MITOLINE™ algorithm, identifying potential anti-cancer treatments. The company is now working on creating a predictive AI model to more efficiently discover novel anti-cancer small molecule scaffolds targeting its SLC25 protein of interest.
SciSparc (Nasdaq: SPRC) ha annunciato che la sua startup, MitoCareX Bio, ha confermato il potenziale coinvolgimento significativo della proteina carrier SLC25 nei tumori polmonari non a piccole cellule (NSCLC). Questa scoperta è stata dimostrata tramite manipolazioni genetiche e sistemi di sfere 3D, che imitano i tumori solidi umani. L'NSCLC, che rappresenta l'80%-85% di tutti i casi di cancro ai polmoni a livello globale, si prevede raggiunga un valore di mercato di 59,77 miliardi di dollari entro il 2030.
MitoCareX ha precedentemente analizzato milioni di piccole molecole utilizzando il suo algoritmo proprietario MITOLINE™, identificando potenziali trattamenti antitumorali. L'azienda sta ora lavorando per creare un modello di intelligenza artificiale predittivo per scoprire in modo più efficiente nuovi schemi di piccole molecole antitumorali mirati alla proteina SLC25 di interesse.
SciSparc (Nasdaq: SPRC) anunció que su empresa emergente, MitoCareX Bio, ha validado la posible participación significativa de su proteína transportadora SLC25 en células de Cáncer de Pulmón no Microcítico (NSCLC). Este descubrimiento se demostró mediante manipulaciones genéticas y sistemas de esferas 3D que imitan los tumores sólidos humanos. El NSCLC, que representa el 80%-85% de todos los casos de cáncer de pulmón a nivel mundial, se proyecta que alcanzará un valor de mercado de 59.77 mil millones de dólares para 2030.
MitoCareX había examinado previamente millones de pequeñas moléculas utilizando su algoritmo propietario MITOLINE™, identificando tratamientos potenciales contra el cáncer. La compañía ahora está trabajando en crear un modelo de IA predictiva para descubrir de manera más eficiente nuevos andamiajes de pequeñas moléculas anticancerígenas dirigidas a su proteína SLC25 de interés.
SciSparc (Nasdaq: SPRC)는 자회사인 MitoCareX Bio가 비소세포폐암(NSCLC) 세포에서 SLC25 운반 단백질의 중요한 역할 가능성을 확인했다고 발표했습니다. 이 발견은 유전자 조작 및 인체 고형 종양을 모방한 3D 구체 시스템을 사용하여 입증되었습니다. NSCLC는 전 세계 폐암 사례의 80%-85%를 차지하며, 2030년까지 597억 7천만 달러의 시장 가치에 이를 것으로 예상됩니다.
MitoCareX는 이전에 독점 알고리즘 MITOLINE™을 사용하여 수백만 개의 소분자를 스크리닝하여 잠재적인 항암 치료제를 식별했습니다. 지금 이 회사는 SLC25 단백질을 타겟으로 하는 새로운 항암 소분자 골격을 보다 효율적으로 발견하기 위한 예측 AI 모델을 만드는 작업을 진행하고 있습니다.
SciSparc (Nasdaq: SPRC) a annoncé que sa filiale, MitoCareX Bio, a validé le potentiel engagement significatif de sa protéine de transport SLC25 dans les cellules de Cancer du Poumon Non à Petites Cellules (NSCLC). Cette découverte a été démontrée à l'aide de manipulations génétiques et de systèmes de sphéroïdes 3D imitant les tumeurs solides humaines. Le NSCLC, représentant 80%-85% de tous les cas de cancer du poumon dans le monde, devrait atteindre une valeur de marché de 59,77 milliards de dollars d'ici 2030.
MitoCareX avait précédemment filtré des millions de petites molécules en utilisant son algorithme propriétaire MITOLINE™, identifiant des traitements anticancéreux potentiels. L'entreprise travaille maintenant à créer un modèle d'IA prédictif pour découvrir plus efficacement de nouveaux échafaudages de petites molécules anticancéreuses ciblant sa protéine SLC25 d'intérêt.
SciSparc (Nasdaq: SPRC) hat bekanntgegeben, dass seine Tochtergesellschaft MitoCareX Bio das potenzielle bedeutende Engagement des Zielproteins SLC25 in Nicht-kleinzelligem Lungenkrebs (NSCLC)-Zellen validiert hat. Diese Entdeckung wurde durch genetische Manipulationen und 3D-Sphäroide, die menschliche solide Tumore nachahmen, demonstriert. NSCLC macht weltweit 80%-85% aller Lungenkrebsfälle aus und wird voraussichtlich bis 2030 einen Marktwert von 59,77 Milliarden US-Dollar erreichen.
MitoCareX hat zuvor Millionen von kleinen Molekülen mit seinem proprietären MITOLINE™-Algorithmus gescreent und potenzielle krebsbekämpfende Behandlungen identifiziert. Das Unternehmen arbeitet nun daran, ein prädiktives KI-Modell zu erstellen, um effizienter neuartige chemische Gerüststrukturen für kleine Moleküle zu entdecken, die auf das SLC25-Protein abzielen.
- Validation of SLC25 carrier protein's potential role in NSCLC
- NSCLC market projected to reach $59.77 billion by 2030
- Identification of potential anti-cancer small molecules
- Development of predictive AI model for more efficient drug discovery
- None.
The validation of the SLC25 carrier protein's role in Non-Small Cell Lung Cancer (NSCLC) is a significant advancement in the understanding and treatment of this disease. NSCLC is a highly prevalent form of lung cancer, making up approximately 80%-85% of cases globally. The discovery by MitoCareX Bio, utilizing genetic manipulations and 3D spheroid systems, is noteworthy because these models closely replicate the main features of human tumors, providing more reliable data.
This finding opens new avenues for targeted therapies, specifically focusing on the mitochondrial SLC25 protein family. If future clinical trials confirm these results, it could lead to breakthroughs in precision medicine, potentially improving treatment efficacy and patient outcomes.
The projections for the NSCLC market to reach $59.77 billion by 2030 underscore the financial potential of any new effective treatment. SciSparc's venture, MitoCareX Bio, is well-positioned to capitalize on this growing market by developing novel therapies targeting the SLC25 protein. This focus on innovation and leveraging advanced computational platforms for drug discovery, like the MITOLINE™ algorithm, positions the company at the forefront of cutting-edge cancer therapeutics.
Given the high global incidence and mortality rate associated with NSCLC, any successful therapeutic development could translate into significant market share and revenue growth for the company, making this an impactful development for investors.
The use of computationally advanced drug discovery platforms, such as the MITOLINE™ algorithm, by MitoCareX Bio, represents a substantial leap in the efficiency and effectiveness of drug discovery. Virtual screening of millions of small molecules and the development of predictive AI models to navigate broader chemical spaces highlight the integration of cutting-edge technology in pharmaceutical research.
These advancements not only speed up the drug discovery process but also increase the likelihood of identifying novel anti-cancer compounds. This tech-driven approach could significantly reduce costs and time-to-market for new therapies, providing a competitive edge for SciSparc and its investors.
The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors
TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and development of cancer therapeutics by targeting the mitochondrial SLC25 protein family, has validated the potential significant involvement of its target SLC25 carrier protein, using Non-Small Cell Lung Cancer (“NSCLC”) cells with diverse genetic backgrounds. MitoCareX demonstrated the discovery by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors.
NSCLC is the most typical form of lung cancer and, according to ResearchAndMarkets.com, the NSCLC Market is projected to reach a value of
Previously, MitoCareX Bio had virtually screened millions of small molecules by using its computationally advanced drug discovery platform, which includes its proprietary MITOLINE™ algorithm. Following the successful virtual screening campaign, MitoCareX identified several small molecules that could potentially be used for anti-cancer treatments.
By utilizing the extensive virtual data generated, MitoCareX is working towards creating a predictive AI model. This model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer small molecule scaffolds that target its SLC25 protein of interest.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on Amazon Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential significant role of MitoCareX’s drug target in NSCLC, the projected size of the NSCLC market, and that MitoCareX’s AI model is expected to enable MitoCareX to navigate broader chemical spaces more efficiently, with the goal of uncovering more novel anti-cancer scaffolds that target its SLC25 protein of interest. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the SEC on April 1, 2024, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What did SciSparc's venture MitoCareX Bio discover about Non-Small Cell Lung Cancer (NSCLC)?
What is the projected market value for Non-Small Cell Lung Cancer (NSCLC) by 2030?
How is MitoCareX Bio advancing its drug discovery process for cancer therapeutics?
What percentage of lung cancer cases does Non-Small Cell Lung Cancer (NSCLC) account for globally?
